TRI-CON: Virtual and Live Options, San Diego, CA USA | February 21-23
The focus for TRI_CON 2022 is Driving Innovation and Collaboration in Diagnostics and Precision Medicine.
Over the past 28 years, the Tri-Conference has served as the leading international meeting place for the precision medicine community. As the world faces the challenges from the pandemic recovery, Cambridge Healthtech Institute once again takes the leadership role of bringing together the life science community at the TRI-CON 2022. Join thousands of international thought leaders —in-person and/or virtually— to discuss the latest research and technologies in precision medicine and precision health; innovation in point-of-care and molecular diagnostics and market access strategies; advanced diagnostics for COVID-19 and other infectious diseases; precision oncology diagnostics and therapeutics; liquid biopsy and minimal residual disease testing; biomarkers and companion diagnostics; and new technologies for spatial multi-omic analysis. Come to sunny San Diego for the in-person networking you’ve come to expect from the Tri-Conference; or join us virtually from the comfort of your home or office for online networking, the cutting-edge scientific program, and convenient on-demand viewing.
About the Digital Pathology Stream
The first digital pathology platform receiving FDA approval has been introduced to the market and is leading to expanded deployment of hardware solutions, along with accompanying software tools and applications. These include slide-free imaging, enterprise-wide solutions and algorithms that use machine learning and AI to improve diagnoses, guide treatment, and address medical challenges across a variety of diseases. The merging of different fields including radiology and pathology is leading to ways of creating digital platforms and streamlining workflows. Fears stemming from how the introduction of these computational tools will impact the pathologist will be addressed, along with a review of emerging companies and approaches seeking to create the pathology diagnosis of the future.